LAPTM4B gene copy number gain is associated with inferior response to anthracycline-based chemotherapy in hormone receptor negative breast carcinomas
ConclusionOur results confirm the possible role of theLAPTM4B gene in anthracycline resistance in HR − breast cancer. AnalyzingLAPTM4B copy number pattern may support future treatment decision.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Drugs & Pharmacology | Fish | Genetics | Hormones | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy